Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis

Published:2024-06-04 Issue:7 Volume:41 Page:2953-2965
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Zhang Libo,Zhang Weilong,Xu Yufeng,Dong Lihou,Sun Yunjuan,Jia Yingmin,Li Zhichuan,Chen Bo,Hou Jie,Zhang Jianzhong

Funder

The studies were supported by KeyMed Biosciences (Chengdu) Co.,Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02887-w.pdf

Reference16 articles.

1. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115–23. https://www.ajmc.com/view/overview-of-atopic-dermatitis-article/. Accessed 2024 Jan 17.

2. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allerg Asthma Immunol. 2018;121(3):340–7. https://doi.org/10.1016/j.anai.2018.07.006.

3. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol. 2013;41(2):73–85. https://doi.org/10.1016/j.aller.2012.03.001.

4. Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. https://doi.org/10.3390/ijms22084130.

5. Clot P-F, Kamal M, Sun J, et al. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: results of two randomized, double-blind, placebo-controlled studies. Int Immunopharmacol. 2021;99:107985. https://doi.org/10.1016/j.intimp.2021.107985.